Clinical Trial Update: S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

A SWOG phase 2 trial evaluating a combination of bortezomib, thalidomide, lenalidomide, and autologous stem cell transplant for newly diagnosed multiple myeloma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Lenalidomide (lenalidomide)
• Thalidomide (thalidomide)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Multiple Myeloma, Plasma Cell Myeloma | Phase 2 | Status: WITHDRAWN